Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX)

Q: What does CUSIP 00972G207 represent in this 13F holders report?

CUSIP 00972G207 is the security identifier for AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value used to aggregate holder disclosures.

Q: How many institutions held AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value in Q4 2025?

21 institutional investors reported AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 00972G207

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Ordinary Shares, $0.000000005 par value
Shares outstanding: 94,284,567,045
Total 13F shares: 4,452,856
Share change: +3,192,966
Total reported value: $1,286,473
Price per share: $0.29
Number of holders: 21
Value change: +$872,091
Number of buys: 10
Number of sells: 6

Quarterly Holders Quick Answers

What is CUSIP 00972G207?
CUSIP 00972G207 identifies AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 00972G207:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Hoyoung Huh	3/4/5	Director, 10%+ Owner	— mixed-class rows	13,621,269 mixed-class rows	$8,631,947	+$1,499,999	16 Dec 2025	3/4/5
Samir R. Patel	3/4/5	Director, 10%+ Owner	— mixed-class rows	5,346,723,013 mixed-class rows	$7,904,201	+$343,750	16 Dec 2025	3/4/5
Raymond Prudo-Chlebosz	3/4/5	Director	— mixed-class rows	5,414,564 mixed-class rows	$4,409,543	+$406,249	16 Dec 2025	3/4/5
Abizer Gaslightwala	3/4/5	CEO, Director	— mixed-class rows	74,789,904 mixed-class rows	$982,195	+$494,159	16 Dec 2025	3/4/5
Cresset Asset Management, LLC	13F	Company	0%	822,468	$830,693	—	30 Sep 2025	13F
Sandip I. Patel	3/4/5	Director	— mixed-class rows	1,397,082 mixed-class rows	$736,057	+$162,499	16 Dec 2025	3/4/5
Robert B. Bazemore	3/4/5	Director	— mixed-class rows	544,521 mixed-class rows	$162,496	+$62,499	16 Dec 2025	3/4/5
Palo Alto Investors LP	13F	Company	0%	146,024	$147,484	—	30 Sep 2025	13F
HighTower Advisors, LLC	13F	Company	0%	79,236	$80,028	—	30 Sep 2025	13F
James R. Neal	3/4/5	Director	— mixed-class rows	269,930 mixed-class rows	$40,624	—	16 Dec 2025	3/4/5
Kameel D. Farag	3/4/5	Interim CFO	— mixed-class rows	76,109 mixed-class rows	$29,963	+$9,999	16 Dec 2025	3/4/5
Omnia Family Wealth, LLC	13F	Company	0%	28,440	$28,724	—	30 Sep 2025	13F
Cerity Partners LLC	13F	Company	0%	23,643	$23,879	—	30 Sep 2025	13F
Virtu Financial LLC	13F	Company	0%	22,502	$22,000	—	30 Sep 2025	13F
TWO SIGMA SECURITIES, LLC	13F	Company	0%	19,753	$19,951	—	30 Sep 2025	13F
Independent Advisor Alliance	13F	Company	0%	10,887	$10,996	—	30 Sep 2025	13F
Accent Capital Management, LLC	13F	Company	0%	10,000	$10,100	—	30 Sep 2025	13F
NewEdge Advisors, LLC	13F	Company	0%	6,800	$6,868	—	30 Sep 2025	13F
Torsten Hombeck	3/4/5	CFO	— mixed-class rows	200,400 mixed-class rows	$468	—	20 Mar 2025	3/4/5
Cornerstone Planning Group LLC	13F	Company	0%	7	$285	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	150	$152	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0%	60	$61	—	30 Sep 2025	13F
Truvestments Capital LLC	13F	Company	0%	50	$51	—	30 Sep 2025	13F
EverSource Wealth Advisors, LLC	13F	Company	0%	44	$44	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	0%	3	$3	—	30 Sep 2025	13F
Rachelle Suzanne Jacques	3/4/5	Chief Executive Officer, Director	— class O/S missing	1,018,027,792	—	—	26 Apr 2024	3/4/5
Wendy F. Dicicco	3/4/5	Interim CFO	— class O/S missing	158,473,915	—	—	01 May 2024	3/4/5
Donald A. Williams	3/4/5	Director	— mixed-class rows	25,000,000 mixed-class rows	—	—	28 Jun 2024	3/4/5
Michael Grissinger	3/4/5	Director	— mixed-class rows	25,000,000 mixed-class rows	—	—	28 Jun 2024	3/4/5
Mohamed Wa'El Ahmed Hashad	3/4/5	Director	— class O/S missing	5,000,000	—	—	28 Jun 2024	3/4/5

Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) as of Q4 2025

As of 31 Dec 2025, Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,452,856 shares. The largest 10 holders included ARMISTICE CAPITAL, LLC, Cresset Asset Management, LLC, Warberg Asset Management LLC, Palo Alto Investors LP, HighTower Advisors, LLC, JANE STREET GROUP, LLC, SmartHarvest Portfolios, LLC, CWA Asset Management Group, LLC, XTX Topco Ltd, and UBS Group AG. This page lists 21 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.